financetom
Business
financetom
/
Business
/
E.l.f. Beauty Insider Sold Shares Worth $3,961,483, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
E.l.f. Beauty Insider Sold Shares Worth $3,961,483, According to a Recent SEC Filing
Apr 23, 2024 2:13 PM

04:49 PM EDT, 04/23/2024 (MT Newswires) -- Kory Marchisotto, Senior Vice President, Chief Marketing Officer, on April 19, 2024, sold 24,992 shares in E.l.f. Beauty (ELF) for $3,961,483. Following the Form 4 filing with the SEC, Marchisotto has control over a total of 131,977 shares of the company, with 131,977 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1600033/000161071724000218/xslF345X03/form4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hyster-Yale Materials Handling Shares Surge After Q1 Results Exceed Estimates
Hyster-Yale Materials Handling Shares Surge After Q1 Results Exceed Estimates
May 8, 2024
01:49 PM EDT, 05/08/2024 (MT Newswires) -- Hyster-Yale Materials Handling ( HY ) shares surged more than 23% in recent Wednesday trading, a day after the company reported better-than-expected Q1 results. Late Tuesday, the company reported Q1 earnings of $2.93 per diluted share, up from $1.55 a year earlier. Analysts polled by Capital IQ expected $2.14. Revenue for the quarter...
--AstraZeneca, Merck Sue Over Cancer Drug Patent Infringement
--AstraZeneca, Merck Sue Over Cancer Drug Patent Infringement
May 8, 2024
01:47 PM EDT, 05/08/2024 (MT Newswires) -- Price: 76.90, Change: +0.58, Percent Change: +0.76 ...
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
May 8, 2024
Wednesday, Teva Pharmaceutical Industries Ltd ( TEVA ) and Medincell announced results from the efficacy portion of the Phase 3 SOLARIS trial of TEV-‘749 in adult patients with schizophrenia compared to placebo. The results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the PANSS total score from baseline after eight weeks compared to placebo. PANSS measures the symptom severity...
Why Match Group Stock Is Down 6% Wednesday
Why Match Group Stock Is Down 6% Wednesday
May 8, 2024
Match Group, Inc ( MTCH ) shares fell Wednesday after the company announced financial results for the first quarter. The Details: Match Group ( MTCH ) reported earnings on Tuesday after the market close that included GAAP EPS of 44 cents, beating analysts estimates of 41 cents, per Benzinga Pro. Match Group ( MTCH ) also reported sales of $859.658...
Copyright 2023-2026 - www.financetom.com All Rights Reserved